Can-Fite BioPharma Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
In a recent press release, Can-Fite BioPharma announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma. This is a significant milestone for the biotechnology company as it seeks to advance its pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases.
Pancreatic cancer is a devastating disease that affects millions of people worldwide. It is known for its aggressive nature and poor prognosis, with a five-year survival rate of less than 10%. Current treatment options for pancreatic cancer are limited, making the need for more effective therapies urgent.
Namodenoson, Can-Fite’s promising drug candidate, has shown great potential in preclinical studies and early-stage clinical trials. It is a highly selective A3 adenosine receptor agonist designed to harness the body’s immune system to fight cancer cells specifically. By targeting the A3 adenosine receptor, Namodenoson activates certain immune cells that can identify and destroy cancer cells, while leaving healthy cells unharmed.
The Orphan Drug Designation is a special status granted by the FDA to drugs or biologics that target rare diseases or conditions that affect fewer than 200,000 people in the United States. This designation provides certain incentives to the pharmaceutical company, including tax credits for qualified clinical testing, exemption from FDA user fees, and seven years of market exclusivity upon approval. It is a pivotal step in Can-Fite’s journey to bring Namodenoson to patients in need.
Dr. Pnina Fishman, Can-Fite’s CEO, expressed optimism about the potential for Namodenoson in the treatment of pancreatic cancer. She stated, We believe Namodenoson has the potential to transform the treatment landscape for pancreatic carcinoma. The Orphan Drug Designation will facilitate our ongoing efforts to expedite the clinical development of Namodenoson, and if approved, will provide us with substantial benefits to bring this much-needed therapy to patients.
Can-Fite’s application for Orphan Drug Designation follows positive results from previous clinical trials, which demonstrated the safety and efficacy of Namodenoson in patients with liver cancer and non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease. The company’s experience in developing Namodenoson for other indications has laid a strong foundation for its potential application in pancreatic cancer.
In addition to its potential in pancreatic cancer, Namodenoson has shown promise in various other indications, including colon cancer, liver cancer, and inflammatory diseases. Can-Fite’s comprehensive approach to targeting both oncological and inflammatory diseases positions the company as a leader in the field of small molecule drug development.
In conclusion, Can-Fite BioPharma’s application for FDA Orphan Drug Designation for Namodenoson in the treatment of pancreatic carcinoma is a significant step forward in the battle against pancreatic cancer. The potential benefits, such as tax credits, market exclusivity, and expedited clinical development, will contribute to the company’s mission of bringing this innovative therapy to patients in need. With its promising preclinical and clinical data, Namodenoson has the potential to transform the treatment landscape for this devastating disease.
Comments